Submit a manuscript Sign up for article alerts Contact us Support

About Clinical and Translational Allergy

This page includes information about the aims and scope of Clinical and Translational Allergy, editorial policies, open access and article-processing charges, the peer review process and other information. For details of how to prepare and submit a manuscript through the online submission system, please see the instructions for authors.

Aims & scope

Clinical and Translational Allergy, one of several journals in the portfolio of the European Academy of Allergy and Clinical Immunology is a peer-reviewed, open access journal which provides a platform for the dissemination of allergy research, reviews, brief communications, as well as EAACI position papers, Task Force Reports and guidelines amongst an international scientific audience.

Open access publishing enables free access to all content ensuring a wide dissemination of articles; the electronic format and expert peer review allows for very rapid publication. Clinical and Translational Allergy is an international journal reaching out far beyond the borders of Europe, and invites clinicians and researchers from all countries of the world to contribute.

Clinical and Translational Allergy accepts clinical, translational and basic research in the following areas and other related topics: asthma, rhinitis, rhinosinusitis, drug hypersensitivity, allergic conjunctivitis, allergic skin diseases, atopic eczema, urticaria, angioedema, venom hypersensitivity, anaphylaxis, food allergy, immunotherapy, immune modulators and biologics, animal models of allergic disease, immune mechanisms, and T cell and B cell functions, or any other topic related to allergic disease. Beyond original research, Clinical and Translational Allergy also accepts structured reviews as well as opinion based reviews, and different position publications from EAACI or its National Societies.

Open access

All articles published by Clinical and Translational Allergy are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.

Authors of articles published in Clinical and Translational Allergy are the copyright holders of their articles and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate the article, according to the BioMed Central copyright and license agreement.

For authors who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed.

Article-processing charges

Open access publishing is not without costs. Clinical and Translational Allergy therefore levies an article-processing charge of £1340/$2095/€1710 for each article accepted for publication. If the corresponding author's institution is a Member, the cost of the article-processing charge is covered by the membership, and no further charge is payable. In the case of authors whose institutions are Supporter Members, however, a discounted article-processing charge is payable by the author. We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page.

Indexing services

All articles published in Clinical and Translational Allergy are included in PubMed, the most widely used biomedical bibliographic database service, which is run by the US National Library of Medicine. Other bibliographic databases that index articles published in Clinical and Translational Allergy include:

  • CAS
  • Embase
  • Google Scholar
  • PubMed
  • PubMed Central

The full text of all research articles is deposited in PubMed Central, the US National Library of Medicine's full-text repository of life science literature, and other digital archives including e-Depot (The Netherlands).

The full text of all research articles published by BioMed Central is also available on SpringerLink.

Clinical and Translational Allergy has an unofficial Impact Factor of 3.41. BioMed Central is working with Thomson Reuters (ISI) to ensure that citation analysis of articles published in Clinical and Translational Allergy will be available.

Publication and peer review process

Content overview

Clinical and Translational Allergy considers the following types of articles:

  • Research: reports of data from original research.
  • Reviews: comprehensive, authoritative, descriptions of any subject within the journal's scope. Reviews are sometimes commissioned from experts in the field, and should have an educational aim.
  • Study protocols: describes proposed or ongoing research, providing a detailed account of the hypothesis, rationale, and methodology of the study.
  • Brief Communications: brief reports of data from original research.

Peer-review policies

Clinical and Translational Allergy operates a closed peer-review policy. The Editor-in-Chief or nominated Handling Editor will invite appropriate reviewers for each manuscript and will take the final decision based on the comments of two concurring reviewer reports.

Authors will be able to check the progress of their manuscript through the submission system at any time by logging into My Clinical and Translational Allergy, a personalized section of the site.


High-quality, bound reprints can be purchased for all articles published. Please see our reprints website for further information about ordering reprints.


Clinical and Translational Allergy will consider supplements based on proceedings (full articles or meeting abstracts), reviews or research. All articles submitted for publication in supplements are subject to peer review. Published supplements are fully searchable and freely accessible online and can also be produced in print. All full length articles (proceedings, reviews or research articles) are indexed by PubMed. PubMed displays the title of the supplement only in the case of meeting abstract collections. For further information, please contact us.

Editorial policies

All manuscripts submitted to Clinical and Translational Allergy should adhere to BioMed Central's editorial policies.

Citing articles in Clinical and Translational Allergy

Articles in Clinical and Translational Allergy should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.

Article citations follow this format:

Authors: Title. Clin Transl Allergy [year], [volume number]:[article number].

e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Clin Transl Allergy 2009, 1:115.

refers to article 115 from Volume 1 of the journal.

Why publish your article in Clinical and Translational Allergy?

High visibility

Clinical and Translational Allergy's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience. Articles that have been especially highly accessed are highlighted with a 'Highly accessed' graphic, which appears on the journal's contents pages and search results.

Speed of publication

Clinical and Translational Allergy offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF; the article will then be available through Clinical and Translational Allergy, BioMed Central and PubMed Central and will also be included in PubMed.


Online publication in Clinical and Translational Allergy gives authors the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).

Promotion and press coverage

Articles published in Clinical and Translational Allergy are included in article alerts and regular email updates. Some may be included in abstract books mailed to academics and are highlighted on Clinical and Translational Allergy's pages and on the BioMed Central homepage.

In addition, articles published in Clinical and Translational Allergy may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Clinical and Translational Allergy. A list of articles recently press-released by journals published by BioMed Central is available here.

Authors of articles published in Clinical and Translational Allergy retain the copyright of their articles and are free to reproduce and disseminate their work (for further details, see the BioMed Central copyright policy and license agreement).

For further information about the advantages of publishing in a journal from BioMed Central, please click here.